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Abstract
Cancer of the exocrine pancreas represents the fifth leading cause of cancer death in the Western
population with an average survival after diagnosis of 3 to 6 months and a five-year survival rate
under 5%. Our understanding of the molecular carcinogenesis has improved in the last few years
due to the development of novel molecular biological techniques. Pancreatic cancer is a multi-stage
process resulting from the accumulation of genetic changes in the somatic DNA of normal cells. In
this article we describe major genetic alterations of pancreatic cancer, mutations in the proto-
oncogene K-RAS and the tumor suppressors INK4A, TP53 and DPC4/SMAD4. The accumulation of
these genetic changes leads to a profound disturbance in cell cycle regulation and continuous
growth. The knowledge of the underlying molecular mechanisms will offer new therapeutic and
diagnostic options and hopefully improve the outcome of this aggressive disease.
Review
Cancer of the exocrine pancreas represents the fifth lead-
ing cause of cancer death in the Western population with
a five-year survival rate under 5% [1]. Because of the few
treatment options, understanding of the molecular pa-
thology is prerequisite to identify potential molecular tar-
gets for drug therapy.
The PanIN (Pancreatic intraepithelial neoplasia) classifi-
cation describes various changes in the pancreatic duct
system distinguishing three PanIN grades (PanIN 1 –
PanIN 3) according to the degree of structural dysplasia
and cytological atypia present in the lesions [2]. Microdis-
section techniques revealed genetic alteration in cancer-
causing genes in the putative premalignant lesions similar
to pancreatic carcinomas (see table 1). The combination
of morphological and genetic observations leads to a tu-
mor progression model for pancreatic carcinoma, compa-
rable to the adenoma-carcinoma sequence in colorectal
carcinomas [3]. The sequential acquisition of mutations
in the proto-oncogene K-RAS and the tumor suppressors
INK4A, TP53 and DPC4/SMAD4 leads to a profound dis-
turbance in cell cycle regulation, a hallmark of pancreatic
cancer. Mutations in K-RAS,  INK4A,  TP53  and  DPC4/
SMAD4  are frequent, whereas mutations in the tumor
suppressor BRCA2, mismatch repair genes and the serine-
threonine kinases AKT2 and LKB1/STK11 are rare genetic
events. Table 1 summarizes the reported frequencies of
major genetic alterations in the pancreatic tumor progres-
sion model.
Genetic alterations with high frequency
Pancreatic cancer has the highest incidence of RAS muta-
tions in human tumors identified to date [4]. The muta-
tions of the K-RAS  gene,  H-RAS  and  N-RAS  are not
affected, are generally found in codon 12. Dependent on
the used technique the frequencies of codon 12 mutations
reported range from 20 to 100% and occur early in the tu-
mor progression model [5,6]. The RAS family proteins en-
code small GTP-binding cytoplasmic proteins that
mediate pleiotropic effects including cell proliferation,
survival and migration [7]. Mutation of codon 12 in K-
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RAS results in a gain of function, because the RAS protein
remains trapped in the activated state. Considering RAS
transforming potential, tissue and species differences
come into question. In general epithelial human cells are
not very sensitive to oncogene transformation. In contrast
primary murine fibroblasts can be efficiently transformed
by mutated RAS in concert with a second oncogene or loss
of a tumor suppressor, like p53 or p16NK4a. The sole ex-
pression of oncogenic RAS in primary rodent and human
cells results in a permanent G1 arrest accompanied by ac-
cumulation of p53, p16INK4A and p21CIP1 [8]. This senes-
cence is thought to be a defense mechanism against
oncogenic stress. Whether the observed overexpression of
p21CIP1, whose frequency parallels that of K-RAS Muta-
tion in the pancreatic tumor progression model, is part of
this defense mechanism or directly linked to the cell cycle
by working as an assembly factor for the cyclin D1/CDK4
complex, is not known [9,10]. Placing p21CIP1 in a de-
fence program is speculative but attractive, because it
could explain in part the observation that oncogenic K-
RAS  mutations are not specific for malignancy, being
present in benign diseases of the pancreas and in early
clonal lesions. Moreover, the risk of progression to malig-
nancy is low in the absence of co-operating genetic events
[11–14]. Despite the high mutation frequency in human
pancreatic carcinoma, mice which harbor a latent allele of
K-Ras G12D capable of spontaneous activation in vivo,
develop multiple early onset lung tumors but not pancre-
atic cancer, further demonstrating the species differences
of RAS function [15]. The complexity of RAS function is
amplified through recent data suggesting tumor suppres-
sor properties of RAS. Transfection of wildtype Ras into rat
fibroblasts inhibits anchorage-independent growth and
colony formation, induced by the oncogenic Ras  gene
[16]. Furthermore – in vivo – Kras2 can inhibit lung car-
cinogenesis in mice [17]. A tumor suppressor function of
K-RAS  might also exist in the pancreas. Loss of the
wildtype K-RAS allele was observed in some pancreatic
carcinoma cell lines with mutation in K-RAS  (ASPC1,
Capan1 and MiaPaca) and there was underexpression of
the mutanted allele in comparison to the wildtype allele
in two other cell lines (Su8686 and Panc1) [5]. A further
species difference affects the signaling pathway utilized by
oncogenic RAS. Whereas in rodent cells the Raf/MAPK
and the PI3K are thought to mediate many effects of on-
cogenic Ras, there are hints that in human cells the gua-
nine nucleotide exchange factor Ral is sufficient for Ras
transformation [18]. Therefore, the net outcome of RAS
activation in a specific setting is not easy to predict and
further studies, including primary cultures of epithelial
pancreas cells, are needed.
Homozygous deletion of p16INK4A/p14ARF locus is a char-
acteristic genetic alteration observed in 80% – 95% of hu-
man pancreatic cancer and usually occurs in later stages of
the tumor progression model [19–21]. This locus on chro-
mosom 9q21 encodes the two related tumor suppressor
genes INK4a and ARF, who's coding sequence partially
overlap. INK4a and ARF are generated by the use of a dif-
ferent first exon and an alternative reading frame in exon
2. Whereas INK4a regulates cell cycle progression as an in-
hibitor of the cyclin D/CDK 4/6 kinase complex, ARF di-
rectly interacts with Mdm 2/HDM 2 to block the
interaction with p53 by localizing Mdm 2/HDM 2 to the
nucleolus and by inhibiting directly Mdm 2/HDM 2's E3
ubiquitin ligase activity, contributing to p53 activation
(figure 1) [22]. Gene deficient mice for p19Arf, the mouse
homologue of human p14ARF, strongly suggest that Arf is
the major tumor suppressor in mice [23,24]. The specific
mutation of the Ink4a  gene in mice also etablishes
p16Ink4a as a tumor suppressor in mice [25,26]. Germline
mutations in the exon 1α of INK4a are associated with the
Familial Atypical Mole-Malignant Melanoma syndrome,
implicating INK4a in human tumor susceptibility [27].
This mutation also predispose to pancreatic cancer, but in
contrast to very high penetrance and early onset of
Table 1: Frequency of major genetic alterations in pancreatic carcinoma.
Gene Reference Normal PanIN1A PanIN1B PanIN2 PanIN3 Carcinoma
K-RAS [6] 0% 38% 44% 87%
[36] 3% 30% 31% 73%
~90%
INK4a [19] 0% 30% 27% 55% 71% 100%
[14] 33% 40%
TP53 [37] 0% 12% 40%
[35] 0% 35% 36% 40%
[36] 0% 0% 0% 9,1% 87%
[9] 0% 0% 0% 20% 57% 47%
DPC4/Smad4 [47] 0% 0% 0% 31% 55%
[ 9 ]0 %0 %0 %0 % 3 3 % 6 6 %Molecular Cancer 2003, 2 http://www.molecular-cancer.com/content/2/1/15
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Figure 1
The INK4a/ARF locus. The two products of the INK4a/ARF locus encodes for p16INK4a and p14ARF (p19Arf in mice). p16INK4a 
indirectly regulates RB function and p14ARF indirectly stabilizes p53.
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melanoma, the penetrance of pancreatic cancer is very low
and displays latency similar to the sporadic disease [28–
30]. In humans INK4a seems to be the more important tu-
mor suppressor for pancreatic cancer development, be-
cause germline and sporadic mutations have been
identified that target INK4a, but omit ARF  [21,31,32].
Mutations that selectively target ARF  are rare findings
[33]. In sporadic tumors INK4a  is inactivated by ho-
mozygous deletions and intragenic mutation and in the
remaining cases the INK4a gene is turned off through pro-
moter methylation [20,34].
The TP53 tumor suppressor gene is mutated, especially by
missense mutations in sequences coding for the DNA
binding domain, in greater than 50% of pancreatic aden-
ocarcinomas. The mutations are often accompanied by
loss of the wildtyp allele and occur late in the progression
model [21,35–39]. The transcription factor p53 regulates
an essential growth checkpoint that both protects against
genomic rearrangement or the accumulation of muta-
tions, and suppresses cellular transformation caused by
oncogene activation or the loss of tumor suppressor path-
ways. p53 is stabilized and activated by extracellular stress
including γ irradiation and intracellular stress such as de-
regulation of cellular oncogenes. Once activated, p53 can
induce cell cycle arrest or apoptosis [40]. Loss of p53 is as-
sociated with aneuploidy, an outstanding feature of pan-
creatic cancer, indicating that p53 function maintains
genomic stability [41,42]. Germline mutations in TP53
have been described as Li-Fraumeni syndrome, predispos-
ing to several neoplasms, but pancreatic carcinomas are
rare findings [43,44]. SMAD4, which was initially named
DPC4, deleted in pancreatic carcinoma, was originally
identified as a candidate tumor suppressor that is fre-
quently inactivated in pancreatic tumors [45]. The tran-
scription factor SMAD4 is an important regulator of the
transforming growth factor β (TGF-β) signaling pathway
[46]. Upon receptor activation SMAD proteins get phos-
phorylated and heterodimerize with Smad4 to transmit
upstream signals to the nucleus and transactivate tran-
scription of specific target genes. The SMAD4 gene is de-
leted or mutated in over 50% of pancreatic carcinoma, an
event occurring late in the tumor progression model
[9,47]. The most prominent biological activity of TGF-β is
its potent inhibition of cell growth, mediated by a cell cy-
cle G1 arrest, in a wide variety of cells. It is assumed that
the growth-inhibitory function of TGF-β is important for
SMAD4 tumor suppressor activity. But recent data also
suggest TGF-β independent SMAD4 function. Restoration
of  SMAD4  in human pancreatic carcinoma cells sup-
pressed tumor formation in vivo and did not restore TGF-
β sensitivity. Furthermore a decrease in pro-angiogenic
VEGF expression and an increase in the angiogenesis in-
hibitor TSP-1 was observed, so that regulation of an ang-
iogenic switch might contribute to the tumor suppressor
function of SMAD4 [48]. Epigenetic inactivation of the
TGF-β/SMAD4 pathway occurs in the presence of activat-
ed RAS, whereby explaining the reduced selection pres-
sure for LOH at the SMAD4 locus [49]. Recent studies
suggest a more aggressive behavior of SMAD4 negative
pancreatic cancers [50,51].
Genetic alterations with low frequency
BRCA2 on chromosome 13q encodes for a protein that is
needed for the maintenance of genomic stability by regu-
lating DNA repair processes. Normal cells, deficient for
BRCA2, accumulate lethal chromosomal aberrations [52].
Inherited BRCA2 mutation predispose to early onset fa-
miliar breast and ovarian cancer [53]. Albeit with lower
penetrance and equal age of onset, inherited BRCA2 mu-
tations also increase the risk for pancreatic cancer [54,55].
In sporadic pancreatic cancer BRCA2 is inactivated in 7 to
10% and lately the biallelic inactivation in a high-grade
duct lesion was demonstrated, so that it is assumed that
BRCA2 mutation occur late in the neoplastic progression
in the pancreas [56].
The autosomal dominant inherited Peutz-Jeghers syn-
drome, caused by mutation of the serine-threonine kinase
LKB1/STK11 that maps to chromosom 19p13, is associat-
ed with an increased incidence of pancreatic carcinoma
[57–60]. The signaling pathway of LKB1/STK1 is so far un-
known, but this gene was shown to be inactivated in 5%
of sporadic pancreatic cancer, suggesting a possible role in
tumor suppression [61,62].
The serine-treonine kinase AKT2 is a candidate oncogene
for human pancreatic cancer and was found to be ampli-
fied and overexpressed in pancreatic adenocarcinoma and
cell lines in up to 20% [63–65]. AKT2 is a downstream ef-
fector of the PI3 kinase and can be activated by epidermal
growth factor, platelet-derived growth factor and basic fi-
broblast growth factor, all known to be overexpressed in
pancreatic carcinoma [66,67]. Recently AKT signaling was
linked to enforced insulin-like growth factor I receptor
expression, promoting invasiveness of pancreatic cancer
cells [68].
Autosomal dominant inherited Lynch syndrome is char-
acterized by an increased risk of developing colorectal, en-
dometrial, ovarian and breast cancers, transitional
carcinoma of the ureter and renal pelvis [69]. Mutations
in the DNA mismatch repair genes, including hMLH1,
hMSH2 and hMSH6, cause this syndrome. Pancreatic can-
cer is included in the tumor spectrum, however, it seems
to be a rare finding [70,71]. Pancreatic cancers occurring
in context of the Lynch syndrome are different compared
to sporadic pancreatic carcinomas in terms of the superior
clinical course, histopathology and distinct molecular ge-
netic profiles, including retention of wildtyp RAS [72–74].Molecular Cancer 2003, 2 http://www.molecular-cancer.com/content/2/1/15
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Furthermore, microsattellite instability is unlikely to par-
ticipate in the oncogenesis of spontaneous pancreatic can-
cer [75–77].
Conclusion
Molecular investigations of pancreatic cancer are compli-
cated by the restricted accessibility of the organ for biop-
sies. The findings in molecular research on pancreatic
carcinoma of the last years is now integrated in a pancre-
atic tumor progression model, with genetically, epigenet-
ically and morphological defined precursor lesions.
Pancreatic cancer is a genetic disease, but the transition
between cancer and non-cancer is not regulated by a sim-
ple switch activated by a single gene. In fact, multiple mu-
tations must accumulate in a single cell, including
overexpression of receptor-ligand systems, oncogene acti-
vation and loss of tumor suppressor genes, to develop
pancreatic carcinoma. But where are the diverse genetic al-
terations, whose number is increasing, integrated? Dereg-
ulated cell cycle is the hallmark of many human tumors,
including pancreatic carcinoma, and therefore the cell cy-
cle could be placed into the center of pancreatic oncogen-
esis. As figure 2 illustrates, each of the major genetic
alteration mentioned above is involved in cell cycle regu-
lation and leads together to the acceleration of the cell cy-
cle progression and continuous growth.
Further analysis of the underlying molecular mechanism
will offer new diagnostic and therapeutic options and,
hopefully improve the outcome of this dismal disease in
the future.
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